Price T Rowe Associates Inc Kal Vista Pharmaceuticals, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KALV
# of Institutions
130Shares Held
46.5MCall Options Held
113KPut Options Held
72K-
Vr Adviser, LLC New York, NY6.25MShares$90.4 Million6.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$60.7 Million2.13% of portfolio
-
Tang Capital Management LLC San Diego, CA4.13MShares$59.7 Million5.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$53.4 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.58MShares$37.3 Million0.06% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $356M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...